Further validation builds on U.S. FDA[1] Breakthrough Device status and inclusion in U.K. NICE[2] recommendations and EASL[3] guidelines Ghent, BELGIUM – 15 May 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant...Read More